All In Biotech

Drug Trial Radar · NCT02842827

A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 With and Without ATRA (Tretinoin) in Patients With Advanced Myeloid Malignancies

Last checked: Nov 19, 2026Latest source record: Jul 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

45

Actual

Start

Oct 6, 2016

Primary completion

Oct 30, 2018

Study completion Oct 30, 2018

Sponsor

Sponsor type
Industry
First posted
Jul 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label study of the dose and duration of an orally administered lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat, in patients with high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Some participants may also receive all-trans retinoic acid (ATRA; also known as tretinoin and Vesanoid®) in combination with bomedemstat. This study investigates the following: * The safety and tolerability of bomedemstat with and without ATRA * The pharmacodynamic effect of different doses of bomedemstat and treatment durations, as well as bomedemstat administered in combination with ATRA * The pharmacokinetics of bomedemstat with and without ATRA

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome

Interventions

  • bomedemstatDrug

    oral administration

  • tretinoinDrug

    oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 24 months
  2. Number of Participants Who Experienced a Serious Adverse Event (SAE)Time frame: Up to approximately 24 months
  3. Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)Time frame: Up to approximately 18 months
  4. Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)Time frame: Up to approximately 28 Days
  5. Number of Participants Experiencing Any Grade 3 to 5 Adverse Events (AE) as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03Time frame: Up to approximately 24 months
  6. Number of Participants Who Experienced a Medical Event of Interest (MEOI)Time frame: Up to approximately 24 months
  7. Maximum Concentration (Cmax) of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
  8. Time to Maximum Concentration (Tmax) of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
  9. Area Under the Concentration Time Curve From Time 0 to 24 Hours (AUC0-24hr) Postdose of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
  10. Elimination Half Life (t1/2) of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
  11. Apparent Total Body Clearance (CL/F) of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
  12. Volume of Distribution (Vz/F) of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
  13. Terminal Elimination Rate Constant (Kel) of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
  14. Event-free Survival (EFS) For High-risk Acute Myeloid Leukemia (AML) ParticipantsTime frame: Up to approximately 24 months
  15. Event-free Survival (EFS) For High-risk Myelodysplastic Syndromes (MDS) ParticipantsTime frame: Up to approximately 24 months
  16. Overall Survival (OS) For High-risk Acute Myeloid Leukemia (AML) ParticipantsTime frame: Up to approximately 24 months
  17. Overall Survival (OS) For High-risk Myelodysplastic Syndromes (MDS) ParticipantsTime frame: Up to approximately 24 months
  18. Objective Response Rate (ORR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the InvestigatorTime frame: Up to approximately 24 months
  19. Best Overall Response (BOR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the InvestigatorTime frame: Up to approximately 24 months
  20. Objective Response Rate (ORR) For High-risk Myelodysplastic Syndromes (MDS) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006) and Assessed by the InvestigatorTime frame: Up to approximately 24 months
  21. Best Overall Response (BOR) Assessed by the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006): High-risk Myelodysplastic Syndromes (MDS) ParticipantsTime frame: Up to approximately 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.